P. Kooij

发表

LOCALISATION OF ENDOCRINE-RELATED TUMOURS WITH RADIOIODINATED ANALOGUE OF SOMATOSTATIN

E. P. Krenning, W. H. Bakker, E. Krenning, 1989, The Lancet.

Safe and effective inhibition of renal uptake of radiolabelled octreotide by a combination of lysine and arginine

R. Valkema, E. Rolleman, E. Krenning, 2002, European Journal of Nuclear Medicine and Molecular Imaging.

Effects of therapy with [177Lu-DOTA0, Tyr3]octreotate in patients with paraganglioma, meningioma, small cell lung carcinoma, and melanoma.

E. Krenning, D. Kwekkeboom, W. D. de Herder, 2006, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Somatostatin receptor-mediated imaging and therapy: basic science, current knowledge, limitations and future perspectives

T. Visser, R. Valkema, E. Krenning, 2001, European Journal of Nuclear Medicine.

Radiolabelled somatostatin analogue(s) for peptide receptor scintigraphy and radionuclide therapy.

R. Valkema, E. Krenning, M. Jong, 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

Comparison of three radiolabelled peptide analogues for CCK-2 receptor scintigraphy in medullary thyroid carcinoma

E. Krenning, A. van der Lugt, W. Breeman, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

Cholecystokinin receptor imaging using an octapeptide DTPA-CCK analogue in patients with medullary thyroid carcinoma

E. Krenning, J. Erion, M. de Jong, 2000, European Journal of Nuclear Medicine.

Bone marrow dosimetry in peptide receptor radionuclide therapy with [177Lu-DOTA0,Tyr3]octreotate

Marion de Jong, Mark Konijnenberg, F. Forrer, 2009, European Journal of Nuclear Medicine and Molecular Imaging.

Subacute haematotoxicity after PRRT with 177Lu-DOTA-octreotate: prognostic factors, incidence and course

E. Krenning, C. V. van Eijck, D. Kwekkeboom, 2015, European Journal of Nuclear Medicine and Molecular Imaging.

Therapy of neuroendocrine tumors with radiolabeled somatostatin-analogues.

R. Valkema, E. Krenning, M. Jong, 1999, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

Nephrotoxicity after PRRT with 177Lu-DOTA-octreotate

E. Krenning, K. Mauff, D. Kwekkeboom, 2016, European Journal of Nuclear Medicine and Molecular Imaging.

Forced hydration prior to renography in children with hydronephrosis. An evaluation.

J. Nauta, P. Kooij, D. Pot, 1991, British journal of urology.

The role of radioactive somatostatin and its analogues in the control of tumor growth.

R. Valkema, E. Krenning, M. Jong, 2000, Recent results in cancer research. Fortschritte der Krebsforschung. Progres dans les recherches sur le cancer.

Scintigraphy and radionuclide therapy with [indium-111-labelled-diethyl triamine penta-acetic acid-D-Phe1]-octreotide.

R. Valkema, E. Krenning, W. Breeman, 1999, Italian journal of gastroenterology and hepatology.

Somatostatin receptor: scintigraphy and radionuclide therapy.

R. Valkema, E. Krenning, W. Breeman, 1996, Digestion.

Radiolabeled somatostatin analog [177Lu-DOTA0,Tyr3]octreotate in patients with endocrine gastroenteropancreatic tumors.

E. Krenning, C. V. van Eijck, D. Kwekkeboom, 2005, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Comparison of 111In-DOTA-Tyr3-octreotide and 111In-DTPA-octreotide in the same patients: biodistribution, kinetics, organ and tumor uptake.

E. Krenning, D. Kwekkeboom, H. Mäcke, 1999, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

E. P. Krenning, W. H. Bakker, A. E. M. Reijs, 1993, European Journal of Nuclear Medicine.

Somatostatin receptor subtype 2-mediated uptake of radiolabelled somatostatin analogues in the human kidney

R. Valkema, E. Rolleman, E. Krenning, 2007, European Journal of Nuclear Medicine and Molecular Imaging.

Comparison of 1!1In-labeled Somatostatin Analogues for Tumor Scintigraphy and Radionuclide Therapy1

Willem, Helmut, Ananth, 2006 .

Comparison of 1 ! 1 In-labeled Somatostatin Analogues for Tumor Scintigraphy and Radionuclide Therapy 1

Joseph, Willem, Helmut, 2006 .

In vivo use of a radioiodinated somatostatin analogue: dynamics, metabolism, and binding to somatostatin receptor-positive tumors in man.

T. Visser, E. Krenning, S. Lamberts, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Somatostatin analogue scintigraphy in carcinoid tumours

E. Krenning, S. Lamberts, D. Kwekkeboom, 1993, European Journal of Nuclear Medicine.

Receptor scintigraphy with a radioiodinated somatostatin analogue: radiolabeling, purification, biologic activity, and in vivo application in animals.

J. Klijn, T. Visser, E. Krenning, 1990, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Somatostatin receptor imaging of endocrine gastrointestinal tumors.

E. Krenning, S. Lamberts, J. Reubi, 1992, Schweizerische medizinische Wochenschrift.

In vivo application of [111In-DTPA-D-Phe1]-octreotide for detection of somatostatin receptor-positive tumors in rats.

T. Visser, E. Krenning, M. Jong, 1991, Life sciences.

Peripheral and axial bone mass in Dutch women. Relationship to age and menopausal state.

H. Pols, J. Birkenhäger, P. Kooij, 1988, The Netherlands journal of medicine.

Endocrine Gastroenteropancreatic Tumors

E. Krenning, D. Kwekkeboom, B. Kam, 2005 .

Bone mass in women with primary biliary cirrhosis: the relation with histological stage and use of glucocorticoids.

H. Pols, J. Birkenhäger, P. Kooij, 1990, Gastroenterology.

et al Treatment with the radiolabeled somatostatinanalog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival Journal of Clinical Oncology :

M. Essen, D. Kwekkeboom, B. Kam, 2008 .

Studies on radiolabeled somatostatin analogues in rats and in patients.

T. Visser, E. Krenning, W. Breeman, 1996, The quarterly journal of nuclear medicine : official publication of the Italian Association of Nuclear Medicine (AIMN) [and] the International Association of Radiopharmacology.

Octreotide scintigraphy for the detection of paragangliomas.

E. Krenning, S. Lamberts, R. Hoogma, 1993, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Effect of dose and specific activity on tissue distribution of indium-111-pentetreotide in rats.

T. Visser, E. Krenning, S. Lamberts, 1995, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Tumor response after [(90)Y-DOTA(0),Tyr(3)]octreotide radionuclide therapy in a transplantable rat tumor model is dependent on tumor size.

T. Visser, B. Bernard, E. Krenning, 2001, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Somatostatin Receptor Scintigraphy: Blazing in Indium and Quenching in Gallium

E. Krenning, M. Jong, W. Breeman, 2020 .

Effect of Dose and Specffic Activity on Tissue Distribution of Indium-lil-Pentetreotide in Rats

W. Breeman, L. Hofland, D. Kwekkeboom, 2006 .

Treatment with the radiolabeled somatostatin analog [177 Lu-DOTA 0,Tyr3]octreotate: toxicity, efficacy, and survival.

E. Krenning, C. V. van Eijck, D. Kwekkeboom, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Treatment of patients with gastro-entero-pancreatic (GEP) tumours with the novel radiolabelled somatostatin analogue [177Lu-DOTA0,Tyr3]octreotate

E. P. Krenning, W. H. Bakker, E. Krenning, 2003, European Journal of Nuclear Medicine and Molecular Imaging.

Lung clearance of intratracheally instilled 99mTc‐tobramycin using pulmonary surfactant as vehicle

Burkhard Lachmann, Per Wollmer, Diederik Gommers, 1999, British journal of pharmacology.

The selenium-75-homocholic acid taurine test reevaluated: combined measurement of fecal selenium-75 activity and 3 alpha-hydroxy bile acids in 211 patients.

P. Kooij, M. van Blankenstein, A. J. van Tilburg, 1991, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Long-term follow-up of renal function after peptide receptor radiation therapy with (90)Y-DOTA(0),Tyr(3)-octreotide and (177)Lu-DOTA(0), Tyr(3)-octreotate.

Marion de Jong, Raffaella Barone, L. Kvols, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

[177Lu-DOTA0,Tyr3]octreotate: comparison with [111In-DTPA0]octreotide in patients

E. Krenning, J. Erion, M. de Jong, 2001, European Journal of Nuclear Medicine.

Phase I study of peptide receptor radionuclide therapy with [In-DTPA]octreotide: the Rotterdam experience.

R. Valkema, E. Krenning, M. Stridsberg, 2002, Seminars in nuclear medicine.

Essentials of peptide receptor scintigraphy with emphasis on the somatostatin analog octreotide.

T. Visser, E. Krenning, S. Lamberts, 1994, Seminars in oncology.

Peptide receptor radionuclide therapy for non-radioiodine-avid differentiated thyroid carcinoma.

E. Krenning, D. Kwekkeboom, J. Teunissen, 2005, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Somatostatin receptor scintigraphy with indium-111-DTPA-D-Phe-1-octreotide in man: metabolism, dosimetry and comparison with iodine-123-Tyr-3-octreotide.

E P Krenning, J C Reubi, T. Visser, 1992, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Clinical validation of fully automated computation of ejection fraction from gated equilibrium blood-pool scintigrams.

J. J. Gerbrands, W. Wijns, W H Bakker, 1983, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Radiotherapy with a Radiolabeled Somatostatin Analogue, [111In‐DTPA‐d‐Phe1]‐Octreotide

T. Visser, E. Krenning, M. Jong, 1994 .

[177Lu-DOTAOTyr3]octreotate: comparison with [111In-DTPAo]octreotide in patients.

E P Krenning, E. Krenning, J. Erion, 2001, European journal of nuclear medicine.

Comparison of [177Lu-DOTA0,Tyr3]octreotate and [177Lu-DOTA0,Tyr3]octreotide: which peptide is preferable for PRRT?

E. P. Krenning, W. H. Bakker, E. Krenning, 2006, European Journal of Nuclear Medicine and Molecular Imaging.

Comparison of (111)In-labeled somatostatin analogues for tumor scintigraphy and radionuclide therapy.

E P Krenning, T. Visser, B. Bernard, 1998, Cancer research.

LEFT VENTRICULAR AND BACKGROUND COUNT DENSITIES AVERAGED OVER ALL STUDIES IN THE THREE DIFFERENT GROUPS LEAP coll

J. J. Gerbrands, M. Simoons, W. Wijns, 2006 .

Radiation dosimetry for indium-111-pentetreotide.

K. Endo, M. Stabin, P. Kooij, 1997, Journal of nuclear medicine : official publication, Society of Nuclear Medicine.

Somatostatin receptor scintigraphy with [111In-DTPA-d-Phe1]- and [123I-Tyr3]-octreotide: the Rotterdam experience with more than 1000 patients

T. Visser, E. Krenning, M. Jong, 1993, European Journal of Nuclear Medicine.

Radiotherapy with a Radiolabeled Somatostatin Analogue, [lllIn-DTPA-~-Phel] -0ctreo tide A Case History

H., M., E. Krenning, 2006 .